Compound ID | 315
ME1036 (CP5609)
Class: Beta-lactam (carbapenem)
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | Cell wall inhibitor; highly potent against Haemophillus infections and MRSA |
| Institute where first reported: | Meiji Seika Kaisha (Meiji Seika Pharma., Japan); licensed to Cerexa (Actavis, Ireland) |
| Year first mentioned: | 2003 |
| Highest developmental phase: | Preclinical |
| Development status: | Inactive |
| Reason Dropped: | Meiji Seika Kaisha have discontinued research of this but rights were licensed to Cerexa who was later taken over by Forest Laboratories, LLC. In 2006 and subsequently in 2014 by Actavis. It is unclear whether this is still active |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/substance/134222972 |
| Citation: |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.